They're not going to make anything, but neither will they lose anything because they're not selling in those countries anyway. So it's a good public deed on their part, which is why I think most of this is public relations.
Based on improving new product visibility, benefits from restructuring initiatives, and near-term volume boost from Medicare Part D supports our Attractive rating for the U.S. pharmaceutical sector.
Recent launches have significantly larger commercial potential than the previous cycle?and [are] likely to drive improving growth prospects post-2006.
Are they going bankrupt? No. But they had a string of bad news like I've never seen before. Bad news has become a norm to the company.
Though this news is clearly a disappointment, we believe that the damage is largely done and the 10 percent decline in the stock price fully compensates for the approximately 8 percent reduction in the earnings outlook for next year.
In addition, we think completion of the company's consent decree obligations is a major psychological positive that could also have financial implications, as spending on consultants and inspections declines.
This is in response to a very challenging environment. I would expect broader cuts to be announced within the sales force, marketing, general and (administration) as well as R&D over the longer run.
We do this all the time. We pay them for their time. Sometimes they do conference calls. Sometimes they prepare slide shows.
Approximately 50% of the cases are filed in the federal court, where standards for scientific evidence are far more rigorous.
Copyright © 2024 Electric Goat Media. All Rights Reserved.